July 4, 2016
OICR congratulates Drs. Mark Levine, Eduardo L. Franco and Gerald Batist, new recipients of the Order of Canada
Three cancer researchers were invested into the Order of Canada over the weekend, including Dr. Mark Levine, C.M., who was honoured for his contributions as an oncologist, researcher and clinician and because he has developed several new treatments for cancer patients that are now used as standard of practice in Canada.
Levine is Director of the Ontario Clinical Oncology Group (OCOG), Chair of the Department of Oncology for the Michael G. DeGroote School of Medicine at McMaster University and a medical oncologist at Juravinski Cancer Centre at Hamilton Health Sciences.
June 1, 2016
Dr. Laurence Klotz of Sunnybrook Health Sciences Centre is a world leader in the field of prostate cancer research. He has been a champion of active surveillance (also known as watchful waiting) for over 20 years, an approach to prostate cancer treatment that has allowed thousands of men with low-risk prostate cancer to avoid or delay therapy by monitoring it closely instead of immediately treating it.
Now Klotz has launched a new clinical trial called PRECISE, funded with $3 million in support by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada, that will use MRI to help to better diagnose prostate cancer without invasive biopsy.
June 1, 2016
Research supported by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada
Toronto, ON – June 1, 2016 – The Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects.
The trial will be led by Dr. Laurence Klotz of the Sunnybrook Research Institute in Toronto, a world leader in the field of prostate cancer research and in the global adoption of active surveillance, a standard practice to monitor patients with low risk prostate cancer.